Kymera Therapeutics, INC Form 4 insider transactions

BVF Partners L.P. and its affiliated entities, including Mark N. Lampert, have significantly increased their beneficial ownership in Kymera Therapeutics, Inc. by acquiring over 317,000 shares in a public offering and receiving new stock options.

Baker Bros. Advisors LP and its affiliated funds, including 667, L.P. and Baker Brothers Life Sciences, L.P., acquired over 1.3 million shares and prefunded warrants in Kymera Therapeutics, Inc. through an underwritten offering that closed on June 30, 2025.

Kymera Therapeutics, Inc. director Felix J. Baker was granted 16,000 non-qualified stock options with an exercise price of $46.47 per share, vesting over one year or by the next annual meeting.

Kymera Therapeutics, Inc. Director Jeffrey W. Albers was granted 16,000 stock options with an exercise price of $46.47, vesting by June 25, 2026, or the next annual meeting.

Kymera Therapeutics, Inc. director Gorjan Hrustanovic was granted 16,000 stock options with an exercise price of $46.47, vesting fully by June 25, 2026, or the next annual meeting.

Kymera Therapeutics, Inc. Director Pamela Esposito was granted 16,000 stock options with an exercise price of $46.47, vesting by June 25, 2026, or the next annual meeting.

Kymera Therapeutics, Inc. Director John Maraganore was granted 16,000 stock options with an exercise price of $46.47, vesting by June 2026 or the next annual meeting.

Kymera Therapeutics, Inc. Director Bruce Booth was granted 16,000 stock options with an exercise price of $46.47, vesting by June 25, 2026, or the next annual meeting.

Kymera Therapeutics, Inc. Director Victor Sandor was granted 16,000 stock options with an exercise price of $46.47, vesting by June 25, 2026, or the next annual meeting.

Kymera Therapeutics, Inc. director Elena Ridloff was granted 16,000 stock options with an exercise price of $46.47, vesting by June 25, 2026, or the next annual meeting.

Elena Ridloff, a Director at Kymera Therapeutics, Inc., executed a pre-planned transaction on June 11, 2025, exercising stock options and simultaneously selling the acquired common stock for a significant profit.

Pamela Esposito, a Director at Kymera Therapeutics, Inc., executed a pre-arranged transaction involving the exercise of stock options and the subsequent sale of common stock on June 3, 2025, as part of a Rule 10b5-1 trading plan.

Kymera Therapeutics Director Elena Ridloff exercised stock options and subsequently sold shares of common stock on June 3, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Kymera Therapeutics, Inc. CEO Nello Mainolfi reported the exercise of stock options and subsequent sale of 30,000 shares of common stock on June 3, 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Kymera Therapeutics, Inc. Director Jeffrey W. Albers executed a pre-arranged transaction, exercising stock options and subsequently selling the acquired common stock.

Kymera Therapeutics, Inc.'s Chief Operating Officer, Jeremy G. Chadwick, sold 2,575 shares of common stock on May 23, 2025, to satisfy tax withholding obligations related to restricted stock unit vesting.

Chief Business Officer Noah Goodman of Kymera Therapeutics acquired 50,000 shares of common stock and options to purchase 100,000 shares, according to a recent SEC filing.

Bruce N. Jacobs, CFO of Kymera Therapeutics, exercised stock options to acquire 25,000 shares of common stock at $2.08 per share on March 31, 2025.

Ellen Chiniara, Chief Legal Officer of Kymera Therapeutics, reports acquisition and disposal of common stock and stock options on March 3, 2025, including sales to cover tax obligations related to vesting RSUs.

Chief Operating Officer of Kymera Therapeutics, Jeremy Chadwick, reports acquisition and disposal of common stock and stock options on March 3, 2025.

Bruce N. Jacobs, CFO of Kymera Therapeutics, reports the acquisition and disposal of common stock and stock options related to vesting restricted stock units.

Chief Medical Officer of Kymera Therapeutics, Jared Gollob, reports acquisition of restricted stock units and stock options, as well as sales of common stock to cover tax obligations.

Kymera Therapeutics CEO Nello Mainolfi was granted stock options for 365,000 shares on March 3, 2025, vesting monthly over three years.

Kymera Therapeutics CEO Nello Mainolfi exercised stock options on January 10, 2025, acquiring 10,000 shares of common stock.

Chief Financial Officer of Kymera Therapeutics, Bruce N. Jacobs, reports exercising stock options and a transaction involving common stock on January 10, 2025.

Ellen Chiniara, Chief Legal Officer of Kymera Therapeutics, sold 3,129 shares of common stock on January 6, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Kymera Therapeutics director, Pamela Esposito, exercised stock options and sold shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Director Pamela Esposito exercised stock options and sold Kymera Therapeutics shares on September 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Jeffrey W. Albers of Kymera Therapeutics, Inc. exercised a stock option and sold 5,000 shares of common stock on August 26, 2024, according to a Form 4 filing with the SEC.

BVF Partners L.P. and its affiliates reported changes in their beneficial ownership of Kymera Therapeutics, Inc. common stock and pre-funded warrants.